Advanced cancer therapy by integrative antitumor actions via systemic administration of miR-499

Journal of Controlled Release

Volumn 181, Issue 1, 2014, Pages 32-39

  Ando, Hidenori ^a   Asai, Tomohiro ^a   Koide, Hiroyuki ^a,b   Okamoto, Ayaka ^a   Maeda, Noriyuki ^c   Tomita, Koji ^c   Dewa, Takehisa ^d   Minamino, Tetsuo ^e   Oku, Naoto ^a  

^a UNIVERSITY OF SHIZUOKA   (Japan)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Nippon Fine Chemical Co Ltd   (Japan)

^d NAGOYA INSTITUTE OF TECHNOLOGY   (Japan)

^e OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Antiangiogenesis; Cancer therapy; Gene delivery; Liposomes; MicroRNA; miR 499

Indexed keywords

CELL ENGINEERING; CYTOLOGY; DISEASES; ENDOTHELIAL CELLS; GENE TRANSFER; LIPOSOMES; MAMMALS; ONCOLOGY; TUMORS;

ANTIANGIOGENESIS; CANCER THERAPY; GENE DELIVERY; MICRORNAS; MIR-499;

MOLECULAR BIOLOGY;

ALANYLPROLYLARGINYLPROLYLGLYCINE; ANTINEOPLASTIC AGENT; CHOLESTEROL; GLYCINE DERIVATIVE; LIPOPLEX; LIPOSOME; MACROGOL; MICRORNA 499; POLYCATION; PROTEIN; TETRAETHYLENEPENTAMINE BASED POLYCATION LIPOSOME; UNCLASSIFIED DRUG; VASCULOTROPIN; ALANYL-PROLYL-ARGINYL-PROLYL-GLYCINE; ANGIOGENESIS INHIBITOR; DRUG CARRIER; ETHYLENEDIAMINE DERIVATIVE; MICRORNA; MIRN499 MICRORNA, HUMAN; OLIGOPEPTIDE; TETRAETHYLENEPENTAMINE; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOMA CELL; COLON CARCINOMA; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG POTENCY; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSFECTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MALE; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; TAIL; TUMOR CELL LINE; TUMOR GROWTH; TUMOR XENOGRAFT; UMBILICAL VEIN ENDOTHELIAL CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; GENE SILENCING; GENE TRANSFER; GENETICS; INTRAVENOUS DRUG ADMINISTRATION; NEOPLASMS, EXPERIMENTAL; PATHOLOGY; TISSUE DISTRIBUTION; TUMOR INVASION;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL LINE, TUMOR; DRUG CARRIERS; ETHYLENEDIAMINES; GENE SILENCING; GENE TRANSFER TECHNIQUES; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INJECTIONS, INTRAVENOUS; LIPOSOMES; MICE; MICRORNAS; NEOPLASM INVASIVENESS; NEOPLASMS, EXPERIMENTAL; OLIGOPEPTIDES; TISSUE DISTRIBUTION; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84896518978     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2014.02.019     Document Type: Article

References (49)

1. A. Lujambio, and S.W. Lowe The microcosmos of cancer Nature 482 2012 347 355
2. K.J. Png, N. Halberg, M. Yoshida, and S.F. Tavazoie A microRNA regulon that mediates endothelial recruitment and metastasis by cancer cells Nature 481 2012 190 194
3. M.S. Zaman, V. Shahryari, G. Deng, S. Thamminana, S. Saini, S. Majid, I. Chang, H. Hirata, K. Ueno, S. Yamamura, K. Singh, Y. Tanaka, Z.L. Tabatabai, and R. Dahiya Up-regulation of microRNA-21 correlates with lower kidney cancer survival PLoS One 7 2012 e31060
4. S. Yoshizawa, J.H. Ohyashiki, M. Ohyashiki, T. Umezu, K. Suzuki, A. Inagaki, S. Iida, and K. Ohyashiki Downregulated plasma miR-92a levels have clinical impact on multiple myeloma and related disorders Blood Cancer J. 2 2012 e53
5. N. Xu, L. Zhang, F. Meisgen, M. Harada, J. Heilborn, B. Homey, D. Grander, M. Stahle, E. Sonkoly, and A. Pivarcsi MicroRNA-125b down-regulates matrix metallopeptidase 13 and inhibits cutaneous squamous cell carcinoma cell proliferation, migration, and invasion J. Biol. Chem. 287 2012 29899 29908
6. N.M. Alajez, M. Lenarduzzi, E. Ito, A.B.Y. Hui, W. Shi, J. Bruce, S.J. Yue, S.H. Huang, W. Xu, J. Waldron, B. O'Sullivan, and F.F. Liu miR-218 suppresses nasopharyngeal cancer progression through downregulation of survivin and the SLIT2-ROBO1 pathway Cancer Res. 71 2011 2381 2391
7. G. Zhao, and B.L. Rodriguez Molecular targeting of liposomal nanoparticles to tumor microenvironment Int. J. Nanomedicine 8 2013 61 71
8. L. Zhu, and V.P. Torchilin Stimulus-responsive nanopreparations for tumor targeting Integr. Biol. (Camb.) 5 2013 96 107
9. M. Halasi, and A.L. Gartel Targeting FOXM1 in cancer Biochem. Pharmacol. 85 2013 644 652
10. L. Li, R. Wang, D. Wilcox, X. Zhao, J. Song, X. Lin, W.M. Kohlbrenner, S.W. Fesik, and Y. Shen Tumor vasculature is a key determinant for the efficiency of nanoparticle-mediated siRNA delivery Gene Ther. 19 2012 775 780
11. V. Catalano, A. Turdo, S. Di Franco, F. Dieli, M. Todaro, and G. Stassi Tumor and its microenvironment: a synergistic interplay Semin. Cancer Biol. 23P 2013 522 532
12. J.X. Wang, J.Q. Jiao, Q. Li, B. Long, K. Wang, J.P. Liu, Y.R. Li, and P.F. Li miR-499 regulates mitochondrial dynamics by targeting calcineurin and dynamin-related protein-1 Nat. Med. 17 2011 71 78
13. K.D. Wilson, S. Hu, S. Venkatasubrahmanyam, J.D. Fu, N. Sun, O.J. Abilez, J.J. Baugh, F. Jia, Z. Ghosh, R.A. Li, A.J. Butte, and J.C. Wu Dynamic microRNA expression programs during cardiac differentiation of human embryonic stem cells: role for miR-499 Circ. Cardiovasc. Genet. 3 2010 426 435
14. K.H. Baek, A. Zaslavsky, R.C. Lynch, C. Britt, Y. Okada, R.J. Siarey, M.W. Lensch, I.H. Park, S.S. Yoon, T. Minami, J.R. Korenberg, J. Folkman, G.Q. Daley, W.C. Aird, Z. Galdzicki, and S. Ryeom Down's syndrome suppression of tumor growth and the role of the calcineurin inhibitor DSCR1 Nature 459 2009 1126 1130
15. A. Courtwright, S. Siamakpour-Reihani, J.L. Arbiser, N. Banet, E. Hilliard, L. Fried, C. Livasy, D. Ketelsen, D.B. Nepal, C.M. Perou, C. Patterson, and N. Klauber-DeMore Secreted frizzle-related protein 2 stimulates angiogenesis via a calcineurin/NFAT signaling pathway Cancer Res. 69 2009 4621 4628
16. A.W. Drzewiecka, M. Ratajewski, W. Wagner, and J. Dastych HIF-1α is up-regulated in activated mast cells by a process that involves calcineurin and NFAT J. Immunol. 181 2008 1665 1672
17. X. Zhang, J.P. Gaspard, and D.C. Chung Regulation of vascular endothelial growth factor by the Wnt and K-ras pathways in colonic neoplasia Cancer Res. 61 2001 6050 6054 (Pubitemid 32762538)
18. S. Huang, K. Shao, Y. Liu, Y. Kuang, J. Li, S. An, Y. Guo, H. Ma, and C. Jiang Tumor-targeting and microenvironment-responsive smart nanoparticles for combination therapy of antiangiogenesis and apoptosis ACS Nano 7 2013 2860 2871
19. V. Perotti, P. Baldassari, I. Bersani, A. Molla, C. Vegetti, E. Tassi, J. Dal Col, R. Dolcetti, A. Anichini, and R. Mortarini NFATc2 is a potential therapeutic target in human melanoma J. Invest. Dermatol. 132 2012 2652 2660
20. E.M. Gallo, M.M. Winslow, K. Cante-Barrett, A.N. Radermacher, L. Ho, L. McGinnis, B. Iritani, J.R. Neilson, and G.R. Crabtree Calcineurin sets the bandwidth for discrimination of signals during thymocyte development Nature 450 2007 731 735 (Pubitemid 350207686)
21. Y. Pei, S.N. Brun, S.L. Markant, W. Lento, P. Gibson, M.M. Taketo, M. Giovannini, R.J. Gilbertson, and R.J. Wechsler-Reya WNT signaling increases proliferation and impairs differentiation of stem cells in the developing cerebellum Development 139 2012 1724 1733
22. T. Asai, S. Matsushita, E. Kenjo, T. Tsuzuku, N. Yonenaga, H. Koide, K. Hatanaka, T. Dewa, M. Nango, N. Maeda, H. Kikuchi, and N. Oku Dicetyl phosphate-tetraethylenepentamine-based liposomes for systemic siRNA delivery Bioconjug. Chem. 22 2011 429 435
23. H. Koide, T. Asai, K. Furuya, T. Tsuzuku, H. Kato, T. Dewa, M. Nango, N. Maeda, and N. Oku Inhibition of Akt (ser473) phosphorylation and rapamycin-resistant cell growth by knockdown of mammalian target of rapamycin with small interfering RNA in vascular endothelial growth factor receptor-1-targeting vector Biol. Pharm. Bull. 34 2011 602 608
24. E. Kenjo, T. Asai, N. Yonenaga, H. Ando, T. Ishii, K. Hatanaka, K. Shimizu, Y. Urita, T. Dewa, M. Nango, H. Tsukada, and N. Oku Systemic delivery of small interfering RNA by use of targeted polycation liposomes for cancer therapy Biol. Pharm. Bull. 36 2013 287 291
25. N. Yonenaga, E. Kenjo, T. Asai, A. Tsuruta, K. Shimizu, T. Dewa, M. Nango, and N. Oku RGD-based active targeting of novel polycation liposomes bearing siRNA for cancer treatment J. Control. Release 160 2012 177 181
26. H. Ando, A. Okamoto, M. Yokota, K. Shimizu, T. Asai, T. Dewa, and N. Oku Development of a miR-92a delivery system for anti-angiogenesis-based cancer therapy J. Gene Med. 15 2013 20 27
27. H. Ando, A. Okamoto, M. Yokota, T. Asai, T. Dewa, and N. Oku Polycation liposomes as a vector for potential intracellular delivery of microRNA J. Gene Med. 15 2013 375 383
28. N. Oku, K. Doi, Y. Namba, and S. Okada Therapeutic effect of adriamycin encapsulated in long-circulating liposomes on Meth-A-sarcoma-bearing mice Int. J. Cancer 58 1994 415 419 (Pubitemid 24254653)
29. A.K. Iyer, A. Singh, S. Ganta, and M.M. Amiji Role of integrated cancer nanomedicine in overcoming drug resistance Adv. Drug Deliv. Rev. 65 2013 1784 1802
30. Y. Huang, S. Goel, D.G. Duda, D. Fukumura, and R.K. Jain Vascular normalization as an emerging strategy to enhance cancer immunotherapy Cancer Res. 73 2013 2943 2948
31. T.R. Spivak-Kroizman, G. Hostetter, R. Posner, M. Aziz, C. Hu, M.J. Demeure, D. Von Hoff, S.R. Hingorani, T.B. Palculict, J. Izzo, G.M. Kiriakova, M. Abdelmelek, G. Bartholomeusz, B.P. James, and G. Powis Hypoxia triggers hedgehog-mediated tumor-stromal interactions in pancreatic cancer Cancer Res. 73 2013 3235 3247
32. X.Q. Liu, Z.Y. Zhang, L. Sun, N. Chai, S.H. Tang, J. Jin, H. Hu, Y.Z. Nie, X. Wang, K.C. Wu, H.F. Jin, and D.M. Fan MicroRNA-499-5p promotes cellular invasion and tumor metastasis in colorectal cancer by targeting FOXO4 and PDCD4 Carcinogenesis 32 2011 1798 1805
33. J.T.C. Shieh, Y. Huang, J. Gilmore, and D. Srivastava Elevated miR-499 levels blunt the cardiac stress response PLoS One 6 2011 e19481
34. J.D. Fu, S.N. Rushing, D.K. Lieu, C.W. Chan, C.W. Kong, L. Geng, K.D. Wilson, N. Chiamvimonvat, K.R. Boheler, J.C. Wu, G. Keller, R.J. Hajjar, and R.A. Li Distinct roles of microRNA-1 and -499 in ventricular specification and functional maturation of human embryonic stem cell-derived cardiomyocytes PLoS One 6 2011 e27417
35. Y. Zhang, N.M. Schwerbrock, A.B. Rogers, W.Y. Kim, and L. Huang Codelivery of VEGF siRNA and gemcitabine monophosphate in a single nanoparticle formulation for effective treatment of NSCLC Mol. Ther. 21 2013 1559 1569
36. S.H. Lee, J. Lee, M.H. Jung, and Y.M. Lee Glyceollins, a novel class of soy phytoalexins, inhibit angiogenesis by blocking the VEGF and bFGF signaling pathways Mol. Nutr. Food Res. 57 2013 225 234
37. J. Xu, J. Wang, B. Xu, H. Ge, X. Zhou, and J.Y. Fang Colorectal cancer cells refractory to anti-VEGF treatment are vulnerable to glycolytic blockade due to persistent impairment of mitochondria Mol. Cancer Ther. 12 2013 717 724
38. M. Talagas, A. Uguen, R. Garlantezec, G. Fournier, L. Doucet, E. Gobin, P. Marcorelles, A. Volant, and M. DE Braekeleer VEGFR1 and NRP1 endothelial expressions predict distant relapse after radical prostatectomy in clinically localized prostate cancer Anticancer Res. 33 2013 2065 2075
39. Y. Murase, T. Asai, Y. Katanasaka, T. Sugiyama, K. Shimizu, N. Maeda, and N. Oku A novel DDS strategy, "dual-targeting", and its application for antineovascular therapy Cancer Lett. 287 2010 165 171
40. H. Koide, T. Asai, H. Kato, N. Yonenaga, H. Ando, T. Dewa, M. Nango, N. Maeda, and N. Oku Susceptibility of PTEN-positive Metastatic Tumors to Small Interfering RNA Targeting the Mammalian Target of Rapamycin 2014 (submitted for publication)
41. Y. Wu, M. Crawford, Y. Mao, R.J. Lee, I.C. Davis, T.S. Elton, L.J. Lee, and S.P. Nana-Sinkam Therapeutic delivery of microRNA-29b by cationic lipoplexes for lung cancer Mol. Ther. Nucleic Acids 2 2013 e84
42. P. Trang, J.F. Wiggins, C.L. Daige, C. Cho, M. Omotola, D. Brown, J.B. Weidhaas, A.G. Bader, and F.J. Slack Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice Mol. Ther. 19 2011 1116 1122
43. S. Vinci, S. Gelmini, I. Mancini, F. Malentacchi, M. Pazzagli, C. Beltrami, P. Pinzani, and C. Orlando Genetic and epigenetic factors in regulation of microRNA in colorectal cancers Methods 59 2013 138 146
44. R.K. Jain Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy Science 307 2005 58 62 (Pubitemid 40093472)
45. N. Cheng, T. Xia, Y. Han, Q.J. He, R. Zhao, and J.R. Ma Synergistic antitumor effects of liposomal honokiol combined with cisplatin in colon cancer models Oncol. Lett. 2 2011 957 962
46. X.L. Guo, D. Li, K. Sun, J. Wang, Y. Liu, J.R. Song, Q.D. Zhao, S.S. Zhang, W.J. Deng, X. Zhao, M.C. Wu, and L.X. Wei Inhibition of autophagy enhances anticancer effects of bevacizumab in hepatocarcinoma J. Mol. Med. 91 2013 473 483
47. K.L. Meadows, and H.I. Hurwitz Anti-VEGF therapies in the clinic Cold Spring Harb. Perspect. Med. 2 2012 a006577
48. V.P. Chauhan, J.D. Martin, H. Liu, D.A. Lacorre, S.R. Jain, S.V. Kozin, T. Stylianopoulos, A.S. Mousa, X. Han, P. Adstamongkonkul, Z. Popovic, P. Huang, M.G. Bawendi, Y. Boucher, and R.K. Jain Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels Nat. Commun. 4 2013 2516
49. B. Diop-Frimpong, V.P. Chauhan, S. Krane, Y. Boucher, and R.K. Jain Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors Proc. Natl. Acad. Sci. U. S. A. 108 2011 2909 2914